Trial Profile
Aliskiren versus lercanidipine in patients with hypertension uncontrolled with two classes of antihypertensives
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 May 2012
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Lercanidipine (Primary) ; Antihypertensives
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASPIV
- 29 Apr 2012 Results presented at the 22nd European Meeting on Hypertension.
- 11 Jul 2011 New trial record
- 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.